Arcturus Therapeutics Stock Gains Attention Ahead of 2026 Trials
Arcturus Therapeutics, a biotech firm, is drawing investor interest with its mRNA therapies for cystic fibrosis and OTC deficiency. Wall Street analysts project significant stock growth.